What is the Torrent Pharma PE ratio today?
Torrent Pharma's PE ratio is 82.0 at the 29 October 2026 close (₹4,580.00 a share): a market capitalisation of ₹1,74,205 crore divided by consolidated net profit of ₹2,124 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit (₹2,163 crore) it is 80.5.
What is the Torrent Pharma debt to equity ratio?
Torrent Pharma's debt-to-equity ratio was 0.76 on 30 September 2026: borrowings of ₹13,874 crore against total equity of ₹18,373 crore. A year earlier, on 30 September 2025, it was 0.31.
What is the Torrent Pharma book value per share?
Torrent Pharma's book value per share was ₹483.04 on 30 September 2026: shareholders' equity of ₹18,373 crore divided by the 38.04 crore shares in issue. The share price at the 29 October 2026 close was ₹4,580.00.
What is the Torrent Pharma PB ratio (price to book value)?
Torrent Pharma's price-to-book (PB) ratio is 9.48 at the 29 October 2026 close: a market capitalisation of ₹1,74,205 crore divided by shareholders' equity (book value) of ₹18,373 crore on 30 September 2026. That is a book value of ₹483.04 per share against a share price of ₹4,580.00.
What is the Torrent Pharma net worth?
Torrent Pharma's net worth — shareholders' equity in its consolidated balance sheet — was ₹18,373 crore on 30 September 2026, up 117.5% from ₹8,449 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹1,74,205 crore at the 29 October 2026 close.
What is the Torrent Pharma ROE and ROCE?
In FY26, Torrent Pharma's return on equity (ROE) was 27.1% and its return on capital employed (ROCE) was 14.9%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 26.5% and ROCE 29.4%.
What is the Torrent Pharma market cap?
Torrent Pharma's market capitalisation was ₹1,74,205 crore (₹1.74 lakh crore) at the 29 October 2026 close: 38.04 crore shares at ₹4,580.00 each.
Is Torrent Pharma debt free?
No. Torrent Pharma had borrowings of ₹13,874 crore on 30 September 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.76. Its cash and current investments were ₹2,986 crore, so its net debt was ₹10,888 crore.
What is the Torrent Pharma EPS?
Torrent Pharma's basic earnings per share (EPS) were ₹63.92 in FY26, against ₹56.47 in FY25.
What is the Torrent Pharma dividend in 2026 and its record date?
In 2026, Torrent Pharma has declared two dividends totalling ₹38 a share: ₹29 (interim) with record date 19 February 2026 and ex-date 18 February 2026 and ₹9 with record date 29 May 2026.
What is the Torrent Pharma promoter holding?
Promoters held 60.78% of Torrent Pharma on 30 September 2026, down 7.53 percentage points from 68.31% the previous quarter and down 7.53 percentage points from 68.31% a year earlier, according to the shareholding pattern filed with NSE.
What is the Torrent Pharma free cash flow?
In FY26, Torrent Pharma generated ₹3,023 crore of cash from operations and spent ₹677 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹2,346 crore. In FY25 it was ₹1,974 crore.
What is the Torrent Pharma shareholding pattern?
On 30 September 2026, Torrent Pharma's shares were held by promoters 60.78%, foreign portfolio investors (FII/FPI) 17.22%, domestic institutions (DII) 13.46% (including mutual funds at 8.82%) and retail and other non-institutional investors 8.54%. Over the year, FII holding was up 1.30 percentage points from 15.92% and DII holding was up 4.18 percentage points from 9.28%.
What are the Torrent Pharma latest quarterly results?
Torrent Pharma's latest results are for Q2 FY27 (July–September 2026), filed on 23 October 2026: consolidated net profit ₹534 crore, down 9.6% from ₹591 crore in Q2 FY26; revenue from operations ₹4,979 crore, up 50.8% year on year.
Torrent Pharma vs Sun Pharma: how do they compare?
In FY26, Torrent Pharma earned net profit of ₹2,163 crore on revenue of ₹13,980 crore, against ₹11,479 crore on ₹58,462 crore for Sun Pharma. Torrent Pharma's operating margin was 24.6% (Sun Pharma 25.3%) and its return on equity 27.1% (Sun Pharma 14.7%). At the 29 October 2026 close, Torrent Pharma's market capitalisation was ₹1,74,205 crore against ₹4,22,517 crore for Sun Pharma, and its PE ratio on FY26 profit 80.5 against 36.8.
What is the Torrent Pharma revenue and profit in FY26?
In FY26 (April 2025–March 2026), Torrent Pharma's consolidated net profit was ₹2,163 crore, up 13.2% from ₹1,911 crore in FY25, on revenue from operations of ₹13,980 crore (up 21.4%). Over three years, from FY23, net profit was up 73.7%.
When are the Torrent Pharma next results?
Torrent Pharma has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.
How does Torrent Pharma compare with its peers?
On FY26 consolidated figures, against Sun Pharma, J.B. Chemicals & Pharmaceuticals and Mankind Pharma: Torrent Pharma's operating margin of 24.6% is the second highest of the four (Sun Pharma 25.3%, J.B. Chemicals & Pharmaceuticals 22.3%, Mankind Pharma 19.1%; peer average 22.2%); its return on equity of 27.1% is the highest of the four (Sun Pharma 14.7%, J.B. Chemicals & Pharmaceuticals 18.7%, Mankind Pharma 12.5%; peer average 15.3%); its revenue growth over three years of 13.3% a year is the second highest of the four (Sun Pharma 10.0% a year, J.B. Chemicals & Pharmaceuticals 9.6% a year, Mankind Pharma 17.7% a year; peer average 12.5% a year).
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
